{"id":"W2083365324","doi":"10.1182/blood-2012-03-414359","title":"An open-label, single-arm, phase 2 (PX-171-004) study of single-agent carfilzomib in bortezomib-naive patients with relapsed and/or refractory multiple myeloma","year":2012,"lang":"en","type":"article","venue":"Blood","topic":"Multiple Myeloma Research and Treatments","field":"Medicine","cited_by":254,"is_retracted":false,"has_abstract":true,"ca_institutions":"Royal Victoria Hospital; University of Alberta; University of Calgary; University of Toronto","funders":"National Cancer Institute","keywords":"Carfilzomib; Bortezomib; Medicine; Multiple myeloma; Nausea; Proteasome inhibitor; Refractory (planetary science); Internal medicine; Adverse effect; Cohort; Clinical endpoint; Oncology; Surgery; Gastroenterology; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001371212,0.002247193,0.002404842,0.0005682343,0.0004113704,0.0008045845,0.0009435203,0.001349601,0.004319591],"category_scores_gemma":[0.0008717884,0.0006100141,0.001018285,0.0003802862,0.0008974758,0.0008953081,0.000431976,0.002982913,0.0008511822],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008917252,"about_ca_system_score_gemma":0.001417714,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007672313,"about_ca_topic_score_gemma":0.00219999,"domain_scores_codex":[0.9995539,0.0002039896,0.0000133071,0.00008664171,0.0000426103,0.00009951812],"domain_scores_gemma":[0.9994226,0.00009098864,0.0001112469,0.00004912932,0.00003211923,0.0002938567],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7150894,0.1324543,0.006227022,0.0005364627,0.000762852,0.0003018019,0.0003277655,0.002615812,0.05645461,0.0002895838,0.0042021,0.08073831],"study_design_scores_gemma":[0.4353507,0.5462481,0.01019766,0.00001531189,0.0002149451,0.0001834112,0.00003475363,0.001310313,0.004072842,0.0001639284,0.002180273,0.00002776213],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9939848,0.0008110705,0.0004709141,0.0002147652,0.00009675232,0.00213457,0.0009747536,0.000120342,0.001192037],"genre_scores_gemma":[0.9836338,0.001068052,0.002780158,0.0007964033,0.0003540189,0.003810653,0.00397319,0.00004585678,0.003537884],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004319591,"threshold_uncertainty_score":0.01445043,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06713614919153943,"score_gpt":0.3382739908904565,"score_spread":0.271137841698917,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}